Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)
- PMID: 24720924
- DOI: 10.1016/j.jchf.2013.12.003
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)
Abstract
Objectives: The objective of this study was to determine the impact of nonfatal cardiovascular (CV) events on changes in health-related quality of life (HRQL).
Background: There is limited understanding of the impact of nonfatal CV events on long-term changes in HRQL in survivors of myocardial infarction (MI).
Methods: The VALIANT (Valsartan In Acute Myocardial Infarction) trial enrolled 14,703 patients post-MI complicated by Killip class II or higher (scale measuring heart failure severity post-MI ranging from class I to IV) and/or reduced ejection fraction. The HRQL substudy included 2,556 (17.4%) patients who completed the EQ-5D with 5 questions, with responses mapped to utility weight on a scale of 0 to 1 and a visual analog scale (VAS) ranging from 0 (worst) to 100 (best) imaginable health state. EQ-5D was administered at baseline and 6, 12, 20, and 24 months. The trajectory of EQ-5D scores was developed by using linear mixed effects regression models with calculation of deviation from this trajectory after nonfatal CV events. Patients who died before the next EQ-5D assessment were excluded.
Results: Over a 2-year period, 597 patients experienced a nonfatal CV event and survived to have another EQ-5D assessment. Their baseline EQ-5D scores were lower than patients without a subsequent nonfatal CV event (VAS 61.0 ± 19 vs 68.2 ± 18 [p < 0.001] and US-based utility score 0.76 ± 0.22 vs 0.83 ± 0.17 [p < 0.001]). These patients with CV events experienced a trajectory-adjusted 6.6 point decrease (p < 0.001) in VAS scores and a 0.07 decrease (p < 0.001) in utility score after the nonfatal CV event.
Conclusions: MI survivors suffering a CV event experienced significantly worse HRQL than their previous trajectory, suggesting that generic instruments can be responsive to nonfatal events. Reduction in nonfatal CV events may affect longitudinal changes in HRQL.
Keywords: heart failure; myocardial infarction; quality of life; utility.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).J Am Coll Cardiol. 2006 Feb 21;47(4):726-33. doi: 10.1016/j.jacc.2005.09.055. Epub 2006 Jan 26. J Am Coll Cardiol. 2006. PMID: 16487836
-
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.Circulation. 2005 Jun 28;111(25):3411-9. doi: 10.1161/CIRCULATIONAHA.104.508093. Epub 2005 Jun 20. Circulation. 2005. PMID: 15967846 Clinical Trial.
-
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.Heart Rhythm. 2007 Mar;4(3):308-13. doi: 10.1016/j.hrthm.2006.11.021. Epub 2006 Nov 29. Heart Rhythm. 2007. PMID: 17341394 Clinical Trial.
-
Valsartan after myocardial infarction.Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S9-13. doi: 10.5152/akd.2014.00002. Anadolu Kardiyol Derg. 2014. PMID: 25604205 Review.
-
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].Nihon Rinsho. 2007 May 28;65 Suppl 5:84-9. Nihon Rinsho. 2007. PMID: 17571370 Review. Japanese. No abstract available.
Cited by
-
Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.Value Health. 2016 Jul-Aug;19(5):537-43. doi: 10.1016/j.jval.2016.02.004. Epub 2016 Apr 6. Value Health. 2016. PMID: 27565270 Free PMC article.
-
Pharmacological interventions for heart failure in people with chronic kidney disease.Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD012466. doi: 10.1002/14651858.CD012466.pub2. Cochrane Database Syst Rev. 2020. PMID: 32103487 Free PMC article.
-
Cost-Effectiveness Analysis of Quadripolar Versus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator Therapy in a Large, Multicenter UK Registry.JACC Clin Electrophysiol. 2017 Feb;3(2):107-116. doi: 10.1016/j.jacep.2016.04.009. JACC Clin Electrophysiol. 2017. PMID: 28280785 Free PMC article.
-
Health-related quality of life in men and women who experienced cardiovascular diseases: Tehran Lipid and Glucose Study.Health Qual Life Outcomes. 2021 Sep 26;19(1):225. doi: 10.1186/s12955-021-01861-2. Health Qual Life Outcomes. 2021. PMID: 34565411 Free PMC article.
-
Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation.Pharmacoeconomics. 2019 Jul;37(7):921-929. doi: 10.1007/s40273-019-00775-8. Pharmacoeconomics. 2019. PMID: 30778865 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical